Innoviva, Inc.INVA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · inva.com
Holds royalty interests in respiratory products partnered with GSK and owns a specialty therapeutics business focused on critical care and infectious disease.
Key ratios
Operating cash flow growth
-4.6%TTM
2025
4.4%2024
33.8%2023
-30.1%
EPS growth
708.3%TTM
2025
811.8%2024
-83.6%2023
-7.0%
FCF / Sales
47.6%2025
2024
52.5%2023
45.3%
Net margin
81.2%TTM
2025
65.9%2024
6.5%2023
57.9%
ROA
7.0%TTM
2025
7.2%2024
8.9%2023
7.1%
ROE
36.7%TTM
2025
29.1%2024
3.4%2023
29.0%
Revenue growth
18.8%TTM
2025
14.7%2024
15.5%2023
-6.3%
Track INVA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer